Phase 3 clinical study of the effect of the drug OV101 (Gaboxadol) in children with Angelman Syndrome

In this study from Ovid Therapeutics, the effectiveness and safety of a new drug, OV101, was tested. A total of 104 participants took part, including a number of Angelman Syndrome patients from the ENCORE expertise center. The study has been completed and the results are expected in early 2021.